NANOG and neoplasm: Recent studies indicate that HHT dose-dependently reduces the viability of MDA-MB-231 cells, decreases the proportion of CD44+/CD24- cells, inhibits tumor sphere formation, and suppresses the expression of Octamer-binding transcription factor 4 (Oct4), CD44, SRY-box transcription factor 2 (Sox2), and Nanog Homeobox (Nanog).